For J&J OTC Sales, Tylenol Arthritis Label Approval Could Bring Relief Closer
This article was originally published in The Tan Sheet
Executive Summary
FDA’s approval positions J&J/McNeil to return Tylenol 8HR Arthritis to the market with new packaging to interest consumers while also sustaining their connection with the iconic brand. The latest label design for the product features different color schemes and text fonts than the most recent previous changes.
You may also be interested in...
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
McNeil scaled up its manufacturing “volume and complexity substantially” following J&J’s acquisition of Pfizer’s consumer business in 2006, says McNeil Consumer VP Shane Freedman. “Just a few years later, we had the recalls” that led eventually to a consent decree with FDA,” he says.
J&J Will Boost OTC Marketing Once Reliable Production Returns
Johnson & Johnson CEO Alex Gorsky says he expects 75% of OTC products previously recalled to be back on the market in 2013, and the firm will begin prioritizing marketing efforts once a consistent supply of products is restored. The McNeil Fort Washington facility will remain offline another year.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.